My Blissel® Time to talk
Video Library

A library of discussions led by national experts Dr Anne Connolly, Dr Diana Mansour and Nurse Specialist Consultant Nikki Noble.
The videos cover a range of very useful, relevant and important topics including, the signs and symptoms of VA, how to make the diagnosis and the impact of vaginal atrophy on a patients quality of life.

Click here to open and play the videos

Time to talk Blissel® Feature video content

How Blissel® Works
Benefits of a gel
How to use the applicator

Ultra low dose estriol vaginal gel1,2

Prescribing and Adverse event reporting information for BlisselⓇ can be found here.

 Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com 

1. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics. 2. Cano A, et al. Menopause. 2012;19(10):1130-9.

Date of preparation: July 2025 | UK-BLS-683(3)

BlisselⓇ (Estriol 50 Micrograms/G Vaginal Gel)
Safety Information:

CLOSE X


  • For the treatment of postmenopausal vaginal atrophy symptoms, local estrogen therapy should only be initiated for symptoms that adversely affect quality of life.
  • BlisselⓇ 50 micrograms/g vaginal gel must not be combined with estrogen preparations for systemic treatment, as there are no studies of safety and risks with estrogen concentrations attained in combination treatment.
  • Intravaginal applicator may cause minor local trauma, especially in women with serious vaginal atrophy.
  • Before estriol treatment is initiated or reinstituted, a complete personal and family medical history should be taken. Physical (including pelvic and breast) examination should be guided by this and by the contraindications and warnings for use.

Please refer to the Summary of Product Characteristics before prescribing.1

1. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.

Common (≥1/100 to <1/10) and (≥1/1000 to <1/100) undesirable effects1


Date of preparation: April 2026 Item code: UK-BLS-671(1)